"The
Report PharmaPoint: Alzheimers Disease - Global Drug Forecast and
Market Analysis to 2023 - Event-Driven Update provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
Alzheimers
Disease (AD) is a progressive neurodegenerative disease that is
characterized by memory loss, cognitive impairment, and functional
decline. During the early stages of disease, sleep disturbances and
forgetfulness are generally the first presenting symptoms. In the
severe stages, patients with AD require permanent observation either
by a home care professional or family member. The rapidly declining
status of patients with AD results in a drastic reduction in quality
of life (QOL), both for the patients and their caretakers. With
rapidly accelerating worldwide prevalence, AD has been identified as
a major global health threat by the international medical community.
Significant efforts have been made to develop a new treatment for AD,
as current pharmacologic management is known to only provide
temporary improvement of symptoms. Without therapies that effectively
stop or reverse the course of the disease, a large area opportunity
exists for the development of an effective pharmacologic approach.
View Report At
:http://www.marketresearchreports.biz/analysis/308756
Highlights
Key Questions Answered
- What are the preferred
therapies for each country?
- The developmental pipeline
consists of disease-modifying therapies (DMTs) that aim to prevent
the disease in early- and presymptomatic patients. Which of these
DMTs will attain high sales revenues during 2013-2023, and in which
markets?
- Will amyloid-based therapies
face adoption challenges in the market? What is the projected uptake
of new passive immunotherapies and BACE inhibitors over the forecast
period?
- How large an impact will
Lundbecks LuAE-58054 and Forum/Mitsubishi Tanabes EVP-6124 have on
the schizophrenia market? What do key opinion leaders think of these
treatment approaches?
- What are the unique
challenges in AD, and how will they affect the growth of the market
globally?
Key Findings
- Guidelines are not closely
followed due to the heterogeneity of symptoms.
- There is a widespread
reluctance to seek treatment in the absence of curative therapies.
- Diagnosis in early stages of
the disease remains a challenge and will affect the growth of the
market over the 2013-2023 forecast period.
- Poor consensus over clinical
trial endpoints required for approval.
- Symptoms related to AD
require better treatment options.
- Amyloid beta is the focus of
the late-stage pipeline.
- Disease-modifying therapies
such as passive immunotherapies and BACE inhibitors will revitalize
the AD market.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/308756
Scope
- Overview of AD and mild
cognitive impairment (MCI), including etiology, general symptoms,
country-specific compliance/caregiving data and epidemiology.
- Annualized AD market revenue,
annual cost of treatment and usage patterns from 2013 and forecast
for ten years to 2023.
- Key topics covered include
strategic competitor assessment, unmet needs, clinical trial mapping
and implications for the AD market.
- Pipeline analysis:
comprehensive data split across AD disease severities for
disease-modifying and symptomatic therapies with novel mechanisms of
action in AD, including Lillys solanezumab, Biogens aducanumab,
Roches gantenerumab and crenezumab (Phase II). Merck & Co.s
M-8931, and Lilly/AstraZenecas AZD-3293.
- Analysis of the current and
future market competition in the global AD drug market. Insightful
review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of
its implications.
Reasons to buy
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most competitive pipelines.
- Develop business strategies
by understanding the trends shaping and driving the AD market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global AD market
in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global AD market from 2013-2023.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
3 Disease Overview 27
3.1 Etiology and
Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 28
3.2 Classification 29
3.2.1 Relapse-Remitting
Multiple Sclerosis 29
3.2.2 Secondary Progressive
Multiple Sclerosis 30
3.2.3 Primary Progressive
Multiple Sclerosis 30
3.2.4 Progressive Relapsing
Multiple Sclerosis 30
3.3 Symptoms 31
3.4 Prognosis 32
3.5 Quality of Life 33
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and
Comorbidities 35
4.2.1 Family members of MS
patients have a 1-5% risk of developing MS 36
4.2.2 Women are twice as likely
to develop MS, but men have a worse prognosis 37
4.2.3 Caucasians have a higher
risk of MS than any other race/ethnicity 37
4.2.4 Protective effect of
vitamin D on MS may relate to latitude and month of birth 37
4.2.5 Timing of environmental
exposures affects MS risk 38
4.2.6 Exposure to smoking may
increase MS risk and worsen prognosis 38
4.2.7 Autoimmune Disease
Comorbidities of MS 39
4.2.8 Mental comorbidities are
found in up to 60% of MS patients and may affect relapse rates 39
4.3 Global Trends 40
4.3.1 North America 40
4.3.2 Europe 41
4.3.3 Asia 41
4.4 Forecast Methodology 42
4.4.1 Sources Used 45
4.4.2 Sources Not Used 51
4.4.3 Forecast Assumptions and
Methods 51
4.5 Epidemiological Forecast of
Multiple Sclerosis (2014-2024) 58
4.5.1 Diagnosed Prevalent Cases
of MS 58
4.5.2 Age-Specific Diagnosed
Prevalent Cases of MS 60 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and
Pathophysiology 26
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Disease Staging Systems 38
3.3 Symptoms 41
3.4 Prognosis 43
3.5 Quality of Life 43
4 Epidemiology 45
4.1 Disease Background 45
4.2 Risk Factors and
Comorbidities 46
4.2.1 A family history of
Alzheimers increases the risk of developing the disease by 7.5 times
47
4.2.2 The APOE
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment